Health Affairs April 30, 2024
From the time that the Centers for Medicare and Medicaid Services (CMS) first provided public guidance on its intended approach for negotiating the price of the first 10 drugs selected for Medicare’s drug price negotiation program, there has been much speculation on the gaps in the available guidance. For example, it’s all well and good to say that a number of factors will be used in negotiation, but how are those factors weighted and used to determine a numeric output, the price? Following closely on the heels of such speculation has been an equal or greater amount of suggestion and recommendation for how CMS might go about this. Now that CMS has made its initial price offers to the makers...
Today's Sponsors
Today's Sponsor